Comparative Benchmarking
In the context of the broader market, RADX competes directly with industry leaders such as XGN and DCGO. With a market capitalization of $53.46M, it holds a significant position in the sector. When comparing efficiency, RADX's gross margin of N/A stands against XGN's 55.35% and DCGO's 27.25%. Such benchmarking helps identify whether Radiopharm Theranostics Ltd is trading at a premium or discount relative to its financial performance.
